Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)

被引：0
作者：
Linde Kehmann
Marie-Luise Berres
Maria Gonzalez-Carmona
Dominik P. Modest
Raphael Mohr
Alexander Wree
Marino Venerito
Christian Strassburg
Verena Keitel
Christian Trautwein
Tom Luedde
Christoph Roderburg
机构：
[1] Charité University Medicine Berlin,Department of Hepatology and Gastroenterology, Campus Virchow Klinikum
[2] Servier Deutschland GmbH,Medical Department III
[3] University Hospital of Aachen,Department of Internal Medicine I
[4] University Hospital of Bonn,Department of Hematology, Oncology and Tumorimmunology
[5] Charité-Universitätsmedizin Berlin,Department of Gastroenterology, Hepatology & Infectious Diseases
[6] Freie Universität Berlin,Clinic for Gastroenterology, Hepatology & Infectious Diseases
[7] Humboldt-Universität Zu Berlin,undefined
[8] and Berlin Institute of Health,undefined
[9] Otto-Von-Guericke University Hospital,undefined
[10] University Hospital of Düsseldorf,undefined
[11] Medical Faculty of Heinrich Heine University Düsseldorf,undefined
来源：
BMC Cancer | / 23卷
关键词：
Chemotherapy; Biliary tract cancer; Cholangiocarcinoma; FTD/TPI (Trifluridine/Tipiracil); Gall bladder carcinoma; Irinotecan; Second-line treatment; Translational research;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 364 条
  • [1] Banales JM(2020)Cholangiocarcinoma 2020: the next horizon in mechanisms and management Nat Rev Gastroenterol Hepatol 17 557-588
  • [2] Marin JJG(2015)Clinical presentation, risk factors and staging systems of cholangiocarcinoma Best Pract Res Clin Gastroenterol 29 245-252
  • [3] Lamarca A(2015)Epidemiology of cholangiocarcinoma Best Pract Res Clin Gastroenterol 29 221-232
  • [4] Rodrigues PM(2010)Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer Expert Rev Gastroenterol Hepatol 4 395-397
  • [5] Khan SA(2022)A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1 J Clin Oncol 40 4_suppl, 378-378-335
  • [6] Roberts LR(2013)Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study Eur J Cancer 49 329-1281
  • [7] Cardinale V(2010)Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 1273-2338
  • [8] Carpino G(2014)Second-line chemotherapy in advanced biliary cancer: a systematic review Ann Oncol 25 2328-701
  • [9] Andersen JB(2021)Second-line FOLFOX chemotherapy (Shitara)versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial Lancet Oncol 22 690-1572
  • [10] Braconi C(2021)Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study Lancet Oncol 22 1560-1402
12345678910